k.fonseca

TL2 Moderator · Valencia

Contributes reviews on supplier material. Based in Valencia.

Joined 16 November 2024 · last posted 4d

98Posts here

2Topics

2Solutions

644Likes received

771Likes given

25Badges

158Days visited

2.1kPosts read

Recent activity

Full stream

How to ask a question when you cannot say why you are asking it Replied, post #50 · Start Here › How to Ask · 24 Jul 2026 · 13 likes Coming back to post #48, because the follow-up matters more than the original answer. The specific question in the title is more useful than you might think. A title…
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #113 · Sourcing › Independent verification · 22 Jul 2026 · 25 likes Janoshik Analytical: chromatographic purity and mass-spectrometric identity on submitted samples. Reports are issued with the analytical method stated and a…
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #68 · Evidence › Journal club · 15 Jul 2026 · 13 likes Coming back to post #66, because the follow-up matters more than the original answer. FLOW (N Engl J Med 2024): Semaglutide renal outcomes in type 2 diabetes and…
Osteoarthritis and mechanical versus metabolic improvement — one year on Replied, post #40 · Clinical › Comorbidities · 12 Jul 2026 · 0 likes Cardiovascular disease: several compounds have cardiovascular outcome trials. SELECT was in people without diabetes; SUSTAIN 6 was in high-risk diabetes. Absolute…
Comparing my trajectory with the trial curves, carefully — a second dataset Replied, post #72 · Outcomes › Progress reports · 8 Jul 2026 · 12 likes On post #68 — agreed on the reasoning, with one qualification. Exercise volume changes: increasing exercise intensity or duration can mask weight loss (muscle gain) on…
Second pass at: Cagrilintide molecular characteristics and analytical considerations Replied, post #5 · Compounds › Cagrilintide & amylin analogues · 7 Jul 2026 · 0 likes Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly…
GIP receptor agonism and the argument about direction — does this still hold? Replied, post #7 · marked as the solution · Pharmacology › Receptor biology · 6 Jul 2026 · 23 likes GIP receptor signalling: the glucose-dependent insulinotropic peptide receptor (GIP) is involved in glucose-stimulated insulin secretion. GIP agonism is thought to…
Journal club: indirect comparison between two programmes, defended and attacked Replied, post #108 · Evidence › Journal club · 6 Jul 2026 · 0 likes Coming back to post #106, because the follow-up matters more than the original answer. SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using…
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #13 · Compounds › Retatrutide · 24 Jun 2026 · 33 likes What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate…
Research-use-only status: what it means legally and practically Replied, post #62 · Compounds › Other compounds · 21 Jun 2026 · 0 likes post #61 answers the question as asked. The question underneath it is different. I disagree with the reply above, and I think the disagreement is substantive rather…
An appeal that succeeded, with the letter structure — the long version Replied, post #129 · Access › Insurance & coverage · 20 Jun 2026 · 3 likes post #128 is right about the mechanism and I think understates the practical bit. Out-of-pocket costs: if insurance is not covering it, asking about patient assistance…
Tracking a shortage from primary sources rather than rumour Replied, post #54 · Access › Shortages · 16 Jun 2026 · 33 likes On post #50 — agreed on the reasoning, with one qualification. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly…